Bausch & Lomb (TSX:BLCO) Other Long-Term Liabilities : C$533 Mil (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb Other Long-Term Liabilities?

Bausch & Lomb's other long-term liabilities for the quarter that ended in Dec. 2023 was C$533 Mil.

Bausch & Lomb's quarterly other long-term liabilities increased from Jun. 2023 (C$454 Mil) to Sep. 2023 (C$478 Mil) and increased from Sep. 2023 (C$478 Mil) to Dec. 2023 (C$533 Mil).

Bausch & Lomb's annual other long-term liabilities increased from Dec. 2021 (C$381 Mil) to Dec. 2022 (C$447 Mil) and increased from Dec. 2022 (C$447 Mil) to Dec. 2023 (C$533 Mil).

Bausch & Lomb Other Long-Term Liabilities Historical Data

The historical data trend for Bausch & Lomb's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb Other Long-Term Liabilities Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Long-Term Liabilities

Get a 7-Day Free Trial

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Long-Term Liabilities	Get a 7-Day Free Trial											-	-	-	-	-

Bausch & Lomb Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

Bausch & Lomb Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » Other Long-Term Liabilities

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.